[Screening of protein kinase inhibitors].
To screen the compounds that inhibit protein kinases, we used an assay system in which activities of protein kinase A, protein kinase C, src family protein tyrosine kinases and eukaryotic elongation factor 2 kinase were simultaneously detected on a single gel for the cytoplasmic protein kinases. For the receptor type protein kinases, EGFR and Flt-1 tyrosine kinases were examined. Here, we briefly described some of the protein kinase inhibitors that have been approved or are under clinical development, and present some novel inhibitors that were found in our screening system.
Uehara
Yoshimasa
Y
National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.
Murakami
Yuko
Y
Fukazawa
Hidesuke
H
D000818:Animals; D002352:Carrier Proteins / Q000592:standards*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000592:standards; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D051379:Mice; D041681:NIH 3T3 Cells; D011493:Protein Kinase C / Q000592:standards; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases / Q000592:standards; D040281:Vascular Endothelial Growth Factor Receptor-1; D019061:src-Family Kinases / Q000592:standards
D002352:Carrier Proteins; D004791:Enzyme Inhibitors; D047908:Intracellular Signaling Peptides and Proteins; D047428:Protein Kinase Inhibitors; C015482:protein kinase modulator; D011505:Protein-Tyrosine Kinases; D040281:Vascular Endothelial Growth Factor Receptor-1; D016044:Fusion Proteins, bcr-abl; D019061:src-Family Kinases; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C